
Eric Singhi/X
Feb 22, 2025, 05:15
Eric K. Singhi: Not all EGFR mutations are the same
Eric K. Singhi, Assistant Professor in the Department of General Oncology at The University of Texas MD Anderson Cancer Center, posted on X:
“Not all EGFR mutations are the same. Dr. Xiuning Le takes us through treatment options for EGFR PACC mutations.
- PACC mutations ~12% of EGFR mutations, often as compound mutations.
- Current SOC is heterogenous.
- Novel TKIs under development.”
Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared this post on X, adding:
“EGFR PACC mutations is one of the fastest moving space in TKI development in lung cancer, together with EGFR ex20 and HER2 ex20. Multiple global phase 3 trials aim to move highly effective TKIs to the first-line setting to render maximal benefit to our patients.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 05:15
Feb 22, 2025, 05:05
Feb 22, 2025, 04:54
Feb 22, 2025, 04:49
Feb 22, 2025, 04:33
Feb 22, 2025, 04:29
Feb 22, 2025, 04:19